ABBVAbbVieRunning, no new patients
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 520 (final count)
- Started
- Mar 15, 2023
- Main results expected
- Apr 2027
- Fully finished
- May 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Assess Progression-free survival (PFS)
Measured over: Up to 4 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05445778 · record last updated 2026-06-02 · checked 2026-11-09 15:47 UTC